| 2008 |
|
|
FDA and the Paul Ehrlich Institute
(Germany) Approve Pluristem's Regulatory Submissions in Support of a
Phase I/II Clinical Trial Utilizing PLX-PAD for Peripheral Artery
Disease
 More ...
|
|
|
Pluristem to Present at LD MICRO Conference
April 29, 2008
More ...
|
|
|
Pluristem to Present to President Bush and Others at
the First Annual Israeli Presidential Conference
More ...
|
|
|
Dutton Associates Announces Investment Opinion:
Pluristem Life Sciences Maintained At Speculative Buy By Dutton
Associates
More ...
|
|
|
Pluristem's PLX Cells Show a Statistically Significant
Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model
More ...
|
|
|
Pluristem's Second Pre-Clinical Study in Ischemic
Stroke Shows Statistically Significant Advantages in Functional and
Anatomical Recovery
More ...
|
|
|
Pluristem Submits Pre-IND Application in Germany to
Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
More ...
|
|
|
Dutton Associates Announces Investment Opinion: Pluristem Therapeutics
Rated Speculative Buy in Update Report by Dutton Associates
More ...
|
|
|
Pluristem Announces Second Clinical Indication Revascularization
Effect After PLX-PAD Therapy
More ...
|
| 2007 |
|
|
Pluristem to Present at the Annual Meeting of the American Society of
Hematology PLX-I Promotes the Engraftment of Human Umbilical Cord
Blood Cells in Animals
More ...
|
|
|
Pluristem's Proprietary PLX Cells Demonstrate Promising Potential in
Treating Autoimmune Disorders
More ...
|
|
|
Pluristem's Reverse Stock Split Effective Today Stock to Trade Under
the New Symbol PSTI
More ...
|
|
|
CORRECTING and REPLACING Pluristem Completes Construction of Its New
GMP Facilities to Support Production for Clinical Trials
More ...
|
|
|
IPluristem Announces a Reverse Stock Split in Conjunction With Its
Application for Listing on the NASDAQ Capital Market
More ...
|
|
|
Independent Study by Fraunhofer Institute in Germany, Using
Pluristem's PLX Cells, Shows Promise in the Treatment of Ischemic
Stroke More ...
|
|
|
Pluristem Life Systems to Present at the Noble Financial Two
Double-0-Seven Small Cap Equity Conference More ...
|
|
|
Pluristem Life Systems to Present at the Noble Financial Two
Double-0-Seven Small Cap Equity Conference More ...
|
|
|
Pluristem's PLX Cells Show Promise in Treating Limb Ischemia More ...
|
|
|
Former CEO of US Bioscience, Inc., Dr. Philip J. Schein, Joins
Pluristem Business Advisory Board More ...
|
|
|
Pluristem and Center for Regenerative Therapies at Charite
University Hospital of Berlin Enters into Collaborative Research Agreement More ...
|
|
|
Pluristem Life Systems Hires American Capital Ventures to Provide Investor
Relations Services
More ...
|
|
|
Pluristem's PLX Cells
Demonstrate Potential to Treat Parkinson's Disease
More ...
|
|
|
Frank Carlucci to Chair
Pluristem Life Systems, Inc. Strategic Business Advisory Board
More ...
|
|
|
Pluristem Receives $830,000
Grant from Israeli Government for Development of the PLX-I Stem Cell
Product
More ...
|
|
|
Pluristem Acquires Patents
and Technology for the Three Dimensional Expansion of Human Cells
More ...
|
|
|
Pluristem Closes on $13.5
Million Private Equity Investment
More ...
|
|
|
Pluristem Shares Commence
Trading on Frankfurt Stock Exchange
More ...
|
|
|
Pluristem to Present Two
Scientific Posters at the International Society for Cellular Therapy
More ...
|
|
|
Pluristem Life Systems,
Inc. Retains Strategic Growth as a Global Investor Relations Advisor
More ...
|
|
|
Dr. William R. Prather,
Senior VP of Corporate Development, is the Featured Guest in an
Audio Interview at SmallCapVoice.com
More ...
|
|
|
Pluristem Life Systems,
Inc. Receives $1.1 Million From Exercise of Warrants
More ...
|
|
|
Pluristem Upgrading Its
Manufacturing Facility to Support $200 Million in Production
Capacity for PLX - I
More ...
|
|
|
Pluristem Announces Scientific Advance in Stem Cell Research; Evidence That PLX Cells Are Immunosuppressive.
More ...
|
|
|
Pluristem Life Systems,
Inc. Announces First Licensing Agreement and Stock Swap With Stem
Cell Innovations, Inc.
More ...
|
|
|
Pluristem Announces Private Equity Investment of $8M
More ...
|
|
|
Pluristem
Announces US FDA Acceptance of its Pre-IND Application to begin
Pre-clinical Studies using PLX- I in Hematological Malignancies
More ...
|
|
|
Pluristem
Announces Evidence That PLX-I Cells Are Immune Privileged
More ...
|
|
|
Pluristem
Appoints Dr. William R. Prather as Senior VP of Corporate
Development
More ...
|
|
|
Pluristem
Submits Pre-Investigational New Drug Document to FDA.
More ...
|
2006 |
|
Pluristem
to Present at Annual Meeting of American Society of Hematology:
Breakthrough Method Improves Engraftment of Umbilical Cord Blood in
Treating Severe Blood Disorders.
More ...
|
|
Pluristem
Appoints Yaky Yanay Chief Financial Officer.
More ...
|
|
Pluristem
Expects to Submit Pre-IND Document to FDA by End of 2006
More ...
|
|
Pluristem
Completes Conversion of Outstanding Convertible Debentures.
More ...
|
|
Pluristem
Upgrades Manufacturing Facilities to Enable Production of First
Biological Product for Phase I Clinical Trials
More ...
|
|
Pluristem
Pre-Clinical Results: Placenta Expanded Cell Therapy Product
Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow
Transplants.
More ...
|
|
Pluristem Selected to Present at International Society
for Experimental Hematology Meeting More ...
|
|
Pluristem to Present at Biotech & Life Sciences Global
Venture Congress in New York City More ...
|
|
Pluristem Receives $470,000 Grant from Israeli
Government to Further Develop PLX-I Stem Cell Product More ...
|
|
Pluristem Life Systems CEO Featured in Exclusive
Interview With WallSt.net More ...
|
|
Pluristem Announces Breakthrough in Bone Marrow
Transplants: Engrafted Cells Increase 2-4 Times in Preclinical Study More ...
|
|
Pluristem Life Systems Retains Biologics Consulting
Group to Pursue FDA Approval of PLX-1 More ...
|
|
Pluristem Life Systems Engages Emerson Gerard
Associates to Mount Media Relations Campaign More ...
|
|
Pluristem Appoints Dr. Edwin Horwitz to Scientific
Advisory Board More ...
|
|
Pluristem Files Patent Application For PLX-1, Intended
as an Innovative Stem Cell Solution For Improved Engraftment During
Bone Marrow Transplantation
More ...
|
|
Pluristem Initiates Pre-Clinical Study for PLX-1, an Innovative Stem
Cell Solution for Improved Engraftment During Bone Marrow
Transplantation
More ...
|
|
Pluristem Announces Closing of 7% Senior Secured Convertible Debenture
Private Placement
More ...
|
|
Pluristem Strengthens Business Strategy Company to Focus on
Commercializing Cell Therapy Products
More ...
|
|
Pluristem Files Patent Application For Expanding Hematopoeitic Stem
Cells (HSC) and Early Progenitor Cells from Cord Blood Non Selected
Mono-Nuclear Cells (MNC)
More ...
|
 |
|
Pluristem Announces Advanced Engineered Cell Graft to Improve
Resurgence of the Hematopoietic Stem Cells in Bone Marrow for Cancer
Patients
More ...
|
2005 |
|
|
Pluristem Ignites Technological Innovation in the Selection and
Separation of Hematopoetic Stem Cells from Cord Blood for Bone
Marrow Transplantation .
More ...
|
|
|
Pluristem Appoits Arnon Nagler, M.D., MSc. to Scientific Advisory
Board
More ...
|
|
|
Pluristem Appoints Dr. Ora Adout-Burger Vice
President of Development
More ...
|
|
|
Pluristem Announces Joint Projects Product Development and Worldwide
Distributorship Agreement with Biological Industries, Ltd.
More ...
|
|
|
Pluristem Obtains Issuance from U.S. Patent Office for Coverage of
Proprietary Stem Cell Expansion Technology .
More ...
|
|
|
Pluristem Board Appoints Zami Aberman as Chief Executive Officer
More ...
|
|
|
Pluristem Obtains Notice of Allowance from U.S. Patent Office
Providing Broad Coverage of Proprietary Stem Cell Expansion
Technology
More ...
|
|
|
Pluristem Completes $3.2 Million Interim Private Placement
More ...
|
|
|
Pluristem Ignites Technological Innovation in the Selection and
Separation of Hematopoetic Stem Cells from Cord Blood for Bone
Marrow Transplantation .
More ...
|
|
|
Pluristem Consummates $755,000 Interim Private Placement
More ...
|
2004 |
|
Pluristem Founder Dr. Shai Meretzki Takes Helm as Acting CEO .
More ...
|
|
|
Pluristem Retains Stem Cell Leader Dr. Avraham -- Avi -- Treves to Consult On Development of Its Products and Technology.
More ...
|
|
|
Pluristem and the Technion -- Israel Institute of Technology Awarded ``Magneton'', Grant from Office of the Chief Scientist .
More ...
|
|
|
Pluristem Chosen To Present At The International Society for Experimental Hematology Annual Meeting -- New Orleans, July 2004.
More ...
|
|
|
Pluristem Announces Appointment of Dr. Menachem -- Mendi -- Ze'evi As Chief Executive Officer
More ...
|
|
|
PLURISTEM LIFE SYSTEMS INC Files SEC form 10QSB, Quarterly Report.
More ...
|
|
|
Pluristem CEO Conducts Live Webcast to Provide Current Status and Forward Momentum
More ...
|
|
|
Pluristem To Present at the 10th Annual Meeting of the International Society for Cellular Therapy -- ISCT --, Dublin, Ireland
More ...
|
|
|
Pluristem to Commence Animal Model Studies Utilizing Proprietary Stem Cell Expansion Technology
More ...
|
|
|
PPluristem Achieves Milestone in Cord Blood Stem Cell Expansion for Transplantation Using its Proprietary PluriX/TM/ Bioreactor System
More ...
|
|
|
Pluristem Announces the Appointment of Prof. Tsvee Lapidot from the Weizmann Institute of Science as Scientific Advisor for Analyzing Pluristem Expansion Technology
More ...
|
|
|
Webcast Alert: Pluristem Life Sciences Presentation at Informed Investors Biotechnology Stocks Virtual Forum to be Webcast on Tuesday, March 9, 2004, 10:00 am ET
More ...
|
|
